ICBII Update on the Road to the Cure - June 2022 · Parkinson's Resource Organization

ICBII Update on the Road to the Cure - June 2022

Category: Newsletter

CHANGES IN VOICE MAY BE AN EARLY INDICATION OF PARKINSON’S DISEASE

Parkinson’s disease, best known for its movement-related symptoms, particularly tremors and stiffness, is also known for changes in sound production, giving those with Parkinson’s a soft monotonous voice. Researchers from the University of Arizona reported that voice changes sometimes appear decades before the movement-related symptoms. These neuroscientists suggest that a specific gene, alpha-synuclein, commonly associated with Parkinson’s may be behind those vocal-related issues – a finding that could help lead to earlier diagnoses and treatments for Parkinson’s patients.

Although the link between alpha-synuclein and Parkinson’s disease is known for more than four decades, the scientific community has failed to develop a drug that can reach the brain and modulate the function of this protein. The reason for this has been the blood-brain barrier (BBB) that stymies the entry of nearly 98% of all pharmaceuticals into the central nervous system. The drugs, such as L-Dopa, that do cross the BBB do nothing to slow down the disease progression, leaving the patients frustrated and helpless who ultimately succumb to the disease.

Good News – La Jolla based ICB International, Inc., (“ICBII”), has developed a BBB permeable alpha-synuclein antibody that has shown unique attributes such as:

Nearly 150-fold higher brain uptake than the classical mouse alpha-synuclein monoclonal antibodies that have been used so far by the scientific community. 

In animal models of Parkinson’s disease, ICBII’s alpha-synuclein-antibody has been shown not only to reach the central nervous system but also eradicated the disease form of alpha-synuclein, ameliorating the motor symptoms of the treated animals.

In addition, ICBII’s antibody has been demonstrated in live animals to quantitate the levels of pathogenic alpha-synuclein by a simple tail-vein injection of radio-labeled antibody followed by a PET scan of the brain. Therefore, ICBII has the technology to potentially diagnose Parkinson’s disease long before the symptoms appear, which no one else can do.

To transform alpha-synuclein antibody into a commercially useable product, ICBII needs to manufacture its drug on a bigger scale and then conduct human clinical trials. The Company is trying to raise funds for the intended purpose.

WOULD YOU LIKE TO HELP get ICBII’s drugs to market faster? The joy of being a part of this historical event can be had by helping ICBI find the funds to bring these trials to fruition through your investing, and by finding others with the financial ability and humanitarian mindset to accomplish the, until now, impossible. Please contact ICBII directly through their website ICBII.com or by phone at 858-455-9880, or contact Jo Rosen at PRO for a personal introduction to the scientists.

IMAGINE the world without Parkinson’s, MSA, or Alzheimer’s disease. JUST IMAGINE.

A Real-Time Science Report

Ram S. Bhatt, PhD., Chief Science Officer

Share This Article:

Google+

Contact Us

Address
Parkinson's Resource Organization
74785 Highway 111
Suite 208
Indian Wells, CA 92210

Local Phone
(760) 773-5628

Toll-Free Phone
(877) 775-4111

General Information
info@parkinsonsresource.org

 

Like! Subscribe! Share!

Did you know that you can communicate with us through Facebook, Twitter, LinkedIn, YouTube, and now Instagram?

PRIVACY POLICY TEXT

 

Updated: August 16, 2017